Reported 3 months ago
CytoReason, an Israeli company specializing in AI-driven disease models, has successfully secured $80 million in funding from notable investors including Nvidia and Pfizer. This investment will allow CytoReason to enhance its applications and expand its proprietary data. The company, which aims to set up a new office in Cambridge, Massachusetts, is already utilized by six of the top ten pharmaceutical firms globally to optimize drug development in various therapeutic areas.
Source: YAHOO